Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Ally Financial
ALLY
5
Bank of America
BAC
US Stock MarketDetailed Quotes
COYA Coya Therapeutics
- 5.690
- -0.070-1.22%
Close May 14 16:00 ET
95.17MMarket Cap-5.32P/E (TTM)
6.045High5.630Low53.72KVolume5.900Open5.760Pre Close308.95KTurnover0.43%Turnover RatioLossP/E (Static)16.72MShares10.24052wk High2.85P/B71.63MFloat Cap4.65052wk Low--Dividend TTM12.59MShs Float10.690Historical High--Div YieldTTM7.21%Amplitude3.210Historical Low5.750Avg Price1Lot Size
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Coya Therapeutics Stock Forum
Revolutionary Frontotemporal Dementia Treatment Prevents Cognitive Decline in All Trial Patients
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study With Low-Dose Il-2 and Ctla4-Ig Combination Treatment in Five Patients With Mild to Moderate Frontotemporal Dementia
Breakthrough: New GLP-1/IL-2 Combo Drug Outperforms Standard Therapy by 42% in Alzheimer's Research
Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)
Monday, 21st April at 9:51 am
COYA 303 is an investigational biologic combination of COYA 301, Coya's low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory therapeutic in autoimmune and ...
Revolutionary Treg Exosome Treatment Could Transform Neurodegenerative Disease Therapy
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program
Wednesday, 26th March at 8:15 am
Regulatory T cell-derived exosomes (Treg exosomes) have demonstrated strong and consistent therapeutic potential in suppressing inflammation in preclinical models of neurodegenerative diseases as previously published here
Treg exosomes are end-stage differentiated, making them less likely to be affected by pro-inflammatory fac...
Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations
Tuesday, 25th February at 8:15 am
Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Dr. Stanley H. Appel, Profess...
Can GLP-1 Agonists Transform Alzheimer's Treatment? Coya Therapeutics Experts Weigh In
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
No comment yet